文献速递前列腺癌

前列腺癌放疗后盆腔并发症及其管理:国际协作叙述性综述

Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.
PubMed 文献 · Eur Urol · 2018-12-17

该协作叙述性综述检索2010年至今文献,评估前列腺癌原发放疗后盆腔毒性发生率和危险因素,并综述其管理。现代放疗技术可在提高剂量同时使毒性增加最小化,高危晚期盆腔毒性不常见,但管理可能具有挑战性,常需侵入性治疗。

要点

  • 中度大分割后晚期G3+胃肠道和泌尿生殖道并发症累积发生率分别高达6%和7%。
  • 近距离放疗联合外照射后晚期泌尿毒性累积发生率高(18%–31%),但患病率较低(4%–14%)。
  • 全盆腔放疗较仅前列腺治疗增加G3+胃肠道毒性且无总生存获益。

核心结论

  • 现代放疗技术进展使更高剂量得以给予,毒性略有增加或相当。
  • 前列腺癌放疗后高危长期毒性不常见,但晚期高危毒性管理具挑战性,难治病例常需侵入性治疗。

研究设计与样本

  • 国际协作叙述性综述,检索2010年至今的文献。

主要发现

  • 常规分割外照射后急性高危盆腔毒性发生率低。
  • 中度大分割后晚期G3+胃肠道和泌尿生殖道并发症粗略累积发生率分别高达6%和7%。
  • 极端大分割后5年G2+泌尿生殖道和胃肠道毒性发生率分别为3%–9%和0%–4%。
  • 近距离放疗单药治疗后晚期G3+泌尿毒性粗略发生率为6%–8%,晚期胃肠道毒性罕见。
  • 联合治疗(外照射和近距离放疗)后晚期泌尿毒性累积发生率为18%–31%,患病率为4%–14%;全盆腔放疗较仅前列腺治疗增加G3+胃肠道毒性且无总生存获益;质子束治疗毒性似乎与当前光子治疗相似。

关键数值与推荐

  • urinary obstruction and urethral stricture are the most common severe urinary toxicities; rectal and urinary bleeding can be recurrent long-term toxicities; hip fracture risk is increased after prostate radiotherapy; literature is mixed on in-field secondary pelvic malignancies; urinary and GI fistulas are rare.
  • 管理可能需侵入性治疗和重建手术治疗难治性和严重症状。

临床怎么用

  • 临床应关注前列腺癌放疗后盆腔毒性,尤其是泌尿梗阻和尿道狭窄等严重毒性。
  • 对于难治性和严重症状,可能需要侵入性治疗和重建手术。

局限性

  • 文献对野外继发性盆腔恶性肿瘤风险结论不一。
  • 需要更高质量研究评估瘘、骨毒性和继发性恶性肿瘤等结局及其管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Radiotherapy used for treating localized prostate cancer is effective at prolonging cancer-specific and overall survival. Still, acute and late pelvic toxicities are a concern, with gastrointestinal (GI) and genitourinary (GU) sequelae being most common as well as other pelvic complications. OBJECTIVE: To present a critical review of the literature regarding the incidence and risk factors of pelvic toxicity following primary radiotherapy for prostate cancer and to provide a narrative review regarding its management. EVIDENCE ACQUISITION: A collaborative narrative review of the literature from 2010 to present was conducted. EVIDENCE SYNTHESIS: Regardless of the modality used, the incidence of acute high-grade pelvic toxicity is low following conventionally fractionated external beam radiotherapy (EBRT). After moderate hypofractionation, the crude cumulative incidences for late grade 3 or higher (G3+) GI and GU complications are as high as 6% and 7%, respectively. After extreme hypofractionation, the 5-yr incidences of G2+ GU and GI toxicities are 3-9% and 0-4%, respectively. Following brachytherapy monotherapy, crude rates of late G3+ GU toxicity range from 6% to 8%, while late GI toxicity is rare. With combination therapy (EBRT and brachytherapy), the cumulative incidence of late GU toxicity is high, between 18% and 31%; however, the prevalence is lower at 4-14%. Whole pelvic radiotherapy remains a controversial treatment option as there is increased G3+ GI toxicity compared with prostate-only treatment, with no overall survival benefit. Proton beam therapy appears to have similar toxicity to photon therapies currently in use. With respect to specific complications, urinary obstruction and urethral stricture are the most common severe urinary toxicities. Rectal and urinary bleeding can be recurrent long-term toxicities. The risk of hip fracture is also increased following prostate radiotherapy. The literature is mixed on the risk of in-field secondary pelvic malignancies following prostate radiotherapy. Urinary and GI fistulas are rare complications. Management of these toxicities may require invasive treatment and reconstructive surgery for refractory and severe symptoms. CONCLUSIONS: There has been progress in the delivery of radiotherapy, enabling the administration of higher doses with minimal tradeoff in terms of slightly increased or equal toxicity. There is a need to focus future improvements in radiotherapy on sparing critical structures to reduce GU and GI morbidities. While complications such as fistulae, bone toxicity, and secondary malignancy are rare, there is a need for higher-quality studies assessing these outcomes and their management. PATIENT SUMMARY: In this report, we review the literature regarding pelvic complications following modern primary prostate cancer radiotherapy and their management. Modern radiotherapy technologies have enabled the administration of higher doses with minimal increases in toxicity. Overall, high-grade long-term toxicity following prostate radiotherapy is uncommon. Management of late high-grade pelvic toxicities can be challenging, with patients often requiring invasive therapies for refractory cases.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Matta R, Chapple CR, Fisch M, et al. Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review. Eur Urol. 2018. PMID: 30573316. doi:10.1016/j.eururo.2018.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。